Company Analysis
Sign in

Olema Pharmaceuticals, Inc. (OLMA)

Nasdaq: OLMA · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.2
◀ Past 5.5● Present 6.0▶ Future 4.2
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Olema Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against none in 2024 and 1 in 2023
Applications published
16
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'13'15'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Olema Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
13 published
Olema Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
8 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,428,379Acylsulfonamide KAT6A inhibitorsPharmaceuticalsOlema Pharmaceuticals, Inc.
Jul 29, 202512,370,181Regimens of estrogen receptor antagonistsPharmaceuticalsOlema Pharmaceuticals, Inc.
Jun 13, 202311,672,785Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugsPharmaceuticalsOlema Pharmaceuticals, Inc.
Jan 25, 202211,229,630Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugsPharmaceuticalsOlema Pharmaceuticals, Inc.
Apr 21, 202010,624,878Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugsPharmaceuticalsOlema Pharmaceuticals, Inc.
May 21, 201910,292,971Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugsPharmaceuticalsOlema Pharmaceuticals, Inc.
Apr 28, 20159,018,244Benzopyran compounds, compositions and uses thereofPharmaceuticalsOlema Pharmaceuticals, Inc.
Nov 22, 20118,063,249Substituted triphenyl butenesOrganic fine chemistryOlema Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 3, 20252025/0214996SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONISTOrganic fine chemistryOlema Pharmaceuticals, Inc.
May 1, 20252025/0136553ACYLSULFONAMIDE KAT6A INHIBITORSPharmaceuticalsOlema Pharmaceuticals, Inc. · patent 12,428,379 granted from it
Feb 20, 20252025/0059204FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORSPharmaceuticalsOlema Pharmaceuticals, Inc.
Feb 13, 20252025/0049768METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASESPharmaceuticalsOlema Pharmaceuticals, Inc.
Jul 11, 20242024/0226073TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGSPharmaceuticalsOlema Pharmaceuticals, Inc.
Apr 25, 20242024/0131013TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGSPharmaceuticalsOlema Pharmaceuticals, Inc.
May 25, 20232023/0159619COMPOSITIONS AND METHODS FOR REGULATING IMMUNE SYSTEM ACTIVITYBiotechnologyOlema Pharmaceuticals, Inc.
Apr 27, 20232023/0129598METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASESPharmaceuticalsOlema Pharmaceuticals, Inc.
Apr 6, 20232023/0109666REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTSPharmaceuticalsOlema Pharmaceuticals, Inc. · patent 12,370,181 granted from it
Nov 24, 20222022/0370421TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGSPharmaceuticalsOlema Pharmaceuticals, Inc. · patent 11,672,785 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OLMA · research, not advice